Our understanding of bone biology and the subsequent development of therapies to treat bone diseases have both expanded greatly in the past 30 years. This article reviews some of the key advances made in these fields during the past decade.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Robling, A. G. et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J. Biol. Chem. 283, 5866–5875 (2008).
Urakawa, I. et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770–774 (2006).
Lyles, K. W. et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med. 357, 1799–809 (2007).
Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756–765 (2009).
McClung, M. R. et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412–420 (2014).
Bolland, M. J., Grey, A., Avenell, A., Gamble, G. D. & Reid, I. R. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 342, d2040 (2011).
Schilcher, J., Michaelsson, K. & Aspenberg, P. Bisphosphonate use and atypical fractures of the femoral shaft. N. Engl. J. Med. 364, 1728–1737 (2011).
Black, D. M. et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296, 2927–2938 (2006).
Kanis, J. A., Johnell, O., Oden, A., Johansson, H. & McCloskey, E. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 19, 385–397 (2008).
Reid, I. R. et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N. Engl. J. Med. 353, 898–908 (2005).
Acknowledgements
I.R.R. thanks J. Cornish, N. Sims and T. J. Martin for advice during the preparation of this manuscript. I.R.R. is supported by the Health Research Council of New Zealand.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
I.R.R. has received research funding from Amgen, Merck and Novartis, and has received honoraria from Amgen, Lilly, Merck, Novartis and Sanofi.
Rights and permissions
About this article
Cite this article
Reid, I. Great strides made but still further to go. Nat Rev Endocrinol 11, 633–634 (2015). https://doi.org/10.1038/nrendo.2015.143
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2015.143
